March 2021

Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson’s disease

Our results reveal that α-syn accumulates within the liver and may be derived from the brain or other peripheral sources. Collectively, our findings indicate that the liver may play a role in the clearance and detoxification of pathological proteins in PD and related synucleinopathies. CLICK TO REVIEW

Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson’s disease Read More »

Impact of rapid eye movement sleep behavior disorder and autonomic disorders on Parkinson’s disease

This article aimed at critically reviewing the literature on the controversies about the prevalence of RBD in PD, the higher incidence of PD non-motor symptoms associated with RBD, the evidence of faster motor worsening in parkinsonian patients with this parasomnia, and the main pathophysiological hypotheses that support these findings. CLICK TO REVIEW

Impact of rapid eye movement sleep behavior disorder and autonomic disorders on Parkinson’s disease Read More »

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota Read More »

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease

Recently, the protective effects of sulforaphane on brain health were also considerably studied, where the studies have further extended to severalneurological diseases, including Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, multiple sclerosis, autism spectrum disorder, and schizophrenia. Animal and cell studies that employ sulforaphane against memory impairment and AD related pre-clinical biomarkers

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease Read More »

“Metal elements and pesticides as risk factors for Parkinson’s disease – A review”

This review provides an outline of our current knowledge on the possible association between metals and PD. We have discussed the potential association between these two, furthermore the chemical properties, biological and toxicological aspects as well as possible mechanisms of Fe, Mn, Cu, Zn, Al, Ca, Pb, Hg and Zn in PD pathogenesis. In addition,

“Metal elements and pesticides as risk factors for Parkinson’s disease – A review” Read More »

Effect of Care Rehabilitation on Medical Expenses, Care Costs, and Total Costs of Elderly Individuals with Parkinson’s Disease

The fast-growing prevalence of Parkinson’s disease (PD) creates a heavy burden for society and the health care system. Although different ways to mitigate the economic burden of PD have been discussed in the literature, including several effective treatments, few studies have paid attention to the effect of care rehabilitation (CR) on PD costs over a

Effect of Care Rehabilitation on Medical Expenses, Care Costs, and Total Costs of Elderly Individuals with Parkinson’s Disease Read More »

Point of View: Open science takes on Parkinson’s disease

The Aligning Science Across Parkinson’s (ASAP) initiative was set up to improve understanding of the biology underlying the onset and progression of Parkinson’s disease. With an emphasis on open science and collaboration, we have assembled a research network led by nearly 100 investigators to explore the pathology of Parkinson’s disease, and this network will soon

Point of View: Open science takes on Parkinson’s disease Read More »

Novel targeted therapies for Parkinson’s disease

Large biomarker development programs are undertaken to identify disease signatures that will improve patient selection and outcome measures in clinical trials. In this review, we summarize PD-related mechanisms that can serve as targets of therapeutic interventions aiming to slow or modify disease progression, as well as previous and ongoing clinical trials in each field, and

Novel targeted therapies for Parkinson’s disease Read More »

A randomization-based causal inference framework for uncovering environmental exposure effects on human gut microbiota

We study the effects of these interventions on the human gut microbiome by testing shifts in microbial diversity, changes in individual microbial abundances, and microbial network wiring between groups of matched subjects via randomization-based inference. In the smoking prevention scenario, we identify a small interconnected group of taxa worth further scrutiny, including Christensenellaceae and Ruminococcaceae

A randomization-based causal inference framework for uncovering environmental exposure effects on human gut microbiota Read More »

Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatographymass spectrometry (LC-MS) to analyse 274 samples

Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease Read More »